WHAT IS CTEPH?
CTEPH is a form of pulmonary hypertension (PH) and is designated as WHO Group 4. CTEPH is defined as1-3:
CTEPH=chronic thromboembolic pulmonary hypertension; WHO=World Health Organization
EVALUATING CTEPH PATIENTS FOR TREATMENT
All patients should be evaluated by CTEPH experts for pulmonary thromboendarterectomy (PTE) surgery.4
Adempas is the first and only FDA-approved therapy to treat adults with inoperable or persistent/recurrent CTEPH. Adempas was predominantly studied in WHO functional class II-III patients.1
V/Q=ventilation/perfusion
PATHOGENESIS
CTEPH may be caused by either single or recurrent pulmonary emboli that incompletely resolve, resulting in endothelialized residua that obstruct or significantly narrow pulmonary arteries.8
CTEPH results from persistent macrovascular obstruction, often associated with vasoconstrictor response, which leads to a secondary small vessel arteriopathy. Small vessel arteriopathy is characterized by medial hypertrophy, intimal proliferation and thickening, microthrombi formation, and plexiform lesions.8
WHO PH CLASSIFICATION9
Identify which WHO group your PH patients are in.
I.PAH
II.PH due to left heart disease
III.PH due to lung disease and/or hypoxia
IV.CTEPH
V.PH with unclear multifactorial mechanism
Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1
PAH=pulmonary arterial hypertension; PH=pulmonary hypertension
Learn about efficacy and safety.
Find out how Adempas can help here.